Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Is Intellia Therapeutics Inc (NTLA) A Good Stock To Buy?

Page 1 of 2

The Insider Monkey team has completed processing the quarterly 13F filings for the September quarter submitted by the hedge funds and other money managers included in our extensive database. Most hedge funds have been producing disappointing net returns in recent years, however that was partly due to the poor performance of small-cap stocks in general. Well, small-cap stocks finally turned the corner and have been beating the large-cap stocks by more than 10 percentage points over the last 5 months.This means the relevancy of hedge funds’ public filings became inarguable, as they may reveal numerous high-potential stocks. The following article will discuss the smart money sentiment towards Intellia Therapeutics Inc (NASDAQ:NTLA).

Intellia Therapeutics Inc (NASDAQ:NTLA) was in 9 hedge funds’ portfolios at the end of September. NTLA investors should pay attention to an increase in support from the world’s most successful money managers in recent months. There were 8 hedge funds in our database with NTLA positions at the end of June. At the end of this article we will also compare NTLA to other stocks including National Presto Industries Inc. (NYSE:NPK), TriCo Bancshares (NASDAQ:TCBK), and Green Plains Partners LP (NASDAQ:GPP) to get a better sense of its popularity.

At Insider Monkey, we’ve developed an investment strategy that has delivered market-beating returns over the past 12 months. Our strategy identifies the 100 best-performing funds of the previous quarter from among the collection of 700+ successful funds that we track in our database, which we accomplish using our returns methodology. We then study the portfolios of those 100 funds using the latest 13F data to uncover the 30 most popular mid-cap stocks (market caps of between $1 billion and $10 billion) among them to hold until the next filing period. This strategy delivered 18% gains over the past 12 months, more than doubling the 8% returns enjoyed by the S&P 500 ETFs.

testing, gene, disrder, double, breakthrough, engineering, disease, technology, medicine, therapy, biology, clinical, strand, chromosomes, health, conceptual, genetics,

Lightspring/Shutterstock.com

What does the smart money think about Intellia Therapeutics Inc (NASDAQ:NTLA)?

At the end of the third quarter, a total of 9 of the hedge funds tracked by Insider Monkey were long this stock, a 13% increase from one quarter earlier. By comparison, 8 hedge funds held shares of the company at the end of June, following its second quarter IPO. So, let’s examine which hedge funds were among the top holders of the stock and which hedge funds were making big moves.

HedgeFundSentimentChart

When looking at the institutional investors followed by Insider Monkey, Samuel Isaly’s OrbiMed Advisors holds the number one position in Intellia Therapeutics Inc (NASDAQ:NTLA). OrbiMed Advisors has a $45.3 million position in the stock. On OrbiMed Advisors’ heels is Julian Baker and Felix Baker’s Baker Bros. Advisors, holding an $18.1 million position. Other members of the smart money with similar optimism comprise Oleg Nodelman’s EcoR1 Capital, Jerome Pfund and Michael Sjostrom’s Sectoral Asset Management, and Millennium Management, one of the 10 largest hedge funds in the world. We should note that none of these hedge funds are among our list of the 100 best performing hedge funds which is based on the performance of their 13F long positions in non-micro-cap stocks.

Page 1 of 2